{
  "docId": "019de075-4aec-72cf-a6e0-519f4b0af11c",
  "docSlug": "80e6ab6db3df4d91b63f99a2a4cf6dc3",
  "documentTitle": "Exscientia | Investor Presentation Deck | 73 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 60,
  "pageCount": 73,
  "prevPage": 59,
  "nextPage": 61,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a definition for MIDD at the bottom left.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4aec-72cf-a6e0-519f4b0af11c/60",
  "deckHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c",
  "deckJsonHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c.json",
  "deckAnchorHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c#slide-60",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.49,
        "y": 0.29
      },
      "kind": "list",
      "text": "Potent, highly selective, reversible and brain penetrant LSD1 inhibitor\nSuitable therapeutic index established with no unexpected toxicity in non-GLP studies\nPotential in broad range of haematologic and oncologic diseases\nPotential as monotherapy or combination therapy\nTranslational work ongoing to define optimal patient populations and validation of PD biomarkers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d92705c-c6e3-4edf-b826-9f899be3a1bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.37,
        "x": 0.075,
        "y": 0.22
      },
      "kind": "list",
      "text": "GLP-tox studies ongoing\nCMC work underway\nMIDD to define best dose and dosing regimen",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ce1bd0d-bcac-4355-8978-c7ee51a44316",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.23,
        "x": 0.075,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "MIDD = Model-informed Drug Development",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38fd5bc1-b688-4512-91d2-688d5a9b4b13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.29,
        "x": 0.075,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘539: Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "079c0571-ac75-4061-9251-36dd0bfdde0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.49,
        "y": 0.23
      },
      "kind": "title",
      "text": "Programme Highlights:",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a954ec3e-85ff-4da5-a95c-5dcff5505885",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "d1013bf1-3dcc-4834-988a-a62d2b3aa642",
      "evidence": "Programme Highlights",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "02ebf716-8af1-4eca-8937-1321b5d2471c",
      "evidence": "The deck presents the consequences of not adopting Exscientia's technology throughout the presentation",
      "position": 0,
      "objective": "What is the cost of not adopting Exscientia's AI-driven precision medicine platform?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 72,
      "from": 29,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c1ff2e13-046f-4a68-9f90-d544bd3e6de9",
      "evidence": "The deck presents information on Exscientia's clinical stage compounds and their potential benefits",
      "position": 1,
      "objective": "What are the potential benefits of Exscientia's clinical stage compounds?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}